Nevertheless, it is important to mention Monaleesa 7, the first phase III trial to study premenopausal ladies, designed specifically to assess the efficacy and safety of ribociclib plus endocrine therapy in 672 premenopausal women with advanced, HR-positive/HER2- negative breast cancer, who had not received previous treatment with cyclin-dependent kinases 4 and 6 inhibitors but who may have received endocrine therapy and chemotherapy in the adjuvant or neoadjuvant setting as well as up to 1 line of chemotherapy for advanced disease. The gene discussed is ERBB2; the disease is breast cancer.